Aurobindo Pharma Ltd vs Jfl Life Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1389 as of 30 Apr 15:30 . The P/E Ratio of Aurobindo Pharma Ltd changed from 9.7 on March 2021 to 19.3 on March 2025 . This represents a CAGR of 14.75% over 5 yearsThe P/E Ratio of JFL Life Sciences Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Aurobindo Pharma Ltd changed from ₹ 51653 crore on March 2021 to ₹ 67951 crore on March 2025 . This represents a CAGR of 5.64% over 5 yearsThe Market Cap of JFL Life Sciences Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Aurobindo Pharma Ltd for the Dec '25 is ₹ 8833 crore as compare to the Sep '25 revenue of ₹ 8407 crore. This represent the growth of 5.07% The revenue of JFL Life Sciences Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Aurobindo Pharma Ltd for the Dec '25 is ₹ 1896 crore as compare to the Sep '25 ebitda of ₹ 1800 crore. This represent the growth of 5.31% The ebitda of JFL Life Sciences Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Aurobindo Pharma Ltd changed from ₹ 918.22 crore to ₹ 909.8 crore over 7 quarters. This represents a CAGR of -0.53% The net profit of JFL Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Aurobindo Pharma Ltd changed from 7.53 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of JFL Life Sciences Ltd changed from 8.33 % on March 2024 to 0 % on March 2025 . This represents a CAGR of -100.00% over 2 years .

About Aurobindo Pharma Ltd

Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in December 1986 as a private limited company.
Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
APL is running with 29 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

About JFL Life Sciences Ltd

JFL Life Sciences Limited was incorporated as JFL Life Sciences Private Limited' on April 25, 2010 as a Private Limited Company.
Pursuant to a Special Resolution held on February 10, 2022, Company converted from a Private Limited to Public Limited Company and name of the Company was changed to JFL Life Sciences Limited', on March 3, 2022.
The Company manufactures and market pharmaceutical products.
The major products are Dry powder injections, Tablets & Capsules (B-Lactam) solid oral dosage form, Tablet and capsules (General) and Oral Rehydration Solutions (ORS). In August 2022, the Company launched an IPO of 29,78,000 Equity Shares by raising funds aggregating to Rs. 18.16 Crore. The Company export products to African countries, Middle Eastern countries and CIS countries, mainly through merchant exporters.

FAQs for the comparison of Aurobindo Pharma Ltd and JFL Life Sciences Ltd

Which company has a larger market capitalization, Aurobindo Pharma Ltd or JFL Life Sciences Ltd?

Market cap of Aurobindo Pharma Ltd is 80,705 Cr while Market cap of JFL Life Sciences Ltd is 62 Cr

What are the key factors driving the stock performance of Aurobindo Pharma Ltd and JFL Life Sciences Ltd?

The stock performance of Aurobindo Pharma Ltd and JFL Life Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aurobindo Pharma Ltd and JFL Life Sciences Ltd?

As of May 4, 2026, the Aurobindo Pharma Ltd stock price is INR ₹1389.55. On the other hand, JFL Life Sciences Ltd stock price is INR ₹9.4.

How do dividend payouts of Aurobindo Pharma Ltd and JFL Life Sciences Ltd compare?

To compare the dividend payouts of Aurobindo Pharma Ltd and JFL Life Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.